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ute. The importance of VEGF in the initiation of diabeticElevated vascular endothelial growth factor in type 1 diabetic
nephropathy remains to be established.patients with diabetic nephropathy.
Background. Growth factors have been suggested to play a
role in the development and progression of diabetic nephropa-
thy. Vascular endothelial growth factor (VEGF) is a potent The Steno hypothesis proposes albuminuria to reflectcytokine family that induces angiogenesis and markedly in-
a more generalized vascular process which affects thecreases endothelial permeability. The aim of the present study
glomeruli in the kidneys, the retina and the intima ofwas to investigate plasma levels of VEGF in a large cohort of
type 1 diabetic patients with diabetic nephropathy and in long- large vessels simultaneously [1]. In diabetic microangio-
standing type 1 diabetic patients with persistent normoalbumi- pathy, the hallmark of endothelial dysfunction is an in-
nuria, and to evaluate VEGF as a predictor of nephropathy crease in permeability and—in proliferative diabetic reti-progression.
nopathy—neovascularization. Vascular endothelial growthMethods. We measured VEGF with an enzyme-linked im-
factor (VEGF)—formerly called vascular permeabilitymunosorbent assay (ELISA) technique in 199 type 1 diabetic
patients with diabetic nephropathy (122 males, age 41 6 10 factor (VPF)—is a potent cytokine family that induces
years, diabetes duration 28 6 8 years), glomerular filtration angiogenesis and markedly increases endothelial perme-
rate (GFR) (median [range]) 75 [10–143] mL/min/1.73 m2, and
ability [2].in 188 long-standing type 1 diabetic patients with persistent
In vitro studies have shown that VEGF is stimulatednormoalbuminuria (115 males, age 43 6 10 years, diabetes
duration 27 6 9 years). One hundred fifty-five of the proteinuric by hyperglycemia, hypoxia, blood pressure elevation, an-
patients were followed for at least 3 years after baseline exami- giotensin II and insulin-like growth factor 1 [2–6]. In
nation with yearly GFR measurements. animals, injection of human recombinant VEGF in the
Results. Plasma levels of VEGF were significantly increased
eyes of non-diabetic monkeys produces many of the vas-in patients with nephropathy as compared to the normoalbumi-
cular abnormalities seen in diabetic retinopathy [7]. Fur-nuric group; (median [range]): 45.7 [22.0–410] versus 27.1
[22.0–355] ng/L, respectively, P , 0.001. This difference was thermore, the level of VEGF is elevated early in the
ascribed to elevated VEGF levels in nephropathic men: 51.8 course of the experimental diabetic eye disease and even
[22.0–410] versus 22.0 [22.0–308] ng/L, P , 0.001. No differ- before the appearance of retinal changes in diabetic rats
ences were found between women with and without nephropa-
[8, 9]. In humans, VEGF was found to be elevated inthy: 37.8 [22.0–325] versus 36.6 [22.0–335] ng/L, NS. In protein-
ocular fluid in diabetic proliferative retinopathy, and theuric patients with GFR above and below the median value,
there was no difference in the level of VEGF, NS. Plasma level of VEGF declined after successful laser photocoag-
VEGF was below the detection limit (22.0 ng/L) in 60 patients ulation [10].
with nephropathy and 93 patients with normoalbuminuria, P , Growth factors have been suggested to play a role in
0.001. The mean rate of GFR decline was 3.5 (SE: 0.4) mL/min/
the development and progression of diabetic nephropa-year, and the following baseline variables acted as predictors of
thy in man [11]. Increased circulating VEGF is probablyprogression: albuminuria, mean arterial blood pressure and
male gender. Hemoglobin A1c and plasma VEGF did not act the best surrogate for increased tissue expression of
as predictors. No significant differences between patients with VEGF; however, VEGF functions primarily as a para-
and without proliferative retinopathy were detected. crine hormone. Therefore, the aim of this study was to
Conclusions. Our data suggest that VEGF is elevated early
investigate plasma levels of VEGF in a large cohort ofin the course of diabetic nephropathy in men with type 1 diabe-
type 1 diabetic patients with diabetic nephropathy andtes mellitus. Baseline albuminuria, arterial blood pressure and
male gender was predictors of diabetic nephropathy progres- in long-standing type 1 diabetic patients with persistent
sion, while plasma VEGF and Hemoglobin A1c did not contrib- normoalbuminuria. The potential role of VEGF as a
predictor of progression in diabetic nephropathy was
evaluated in all (N 5 155) of the above-mentioned pro-Key words: vascular endothelial growth factor, diabetic nephropathy,
progression promoters, retinopathy. teinuric patients followed with yearly glomerular filtra-
tion rate (GFR) measurements for at least 3 years.Ó 2000 by the International Society of Nephrology
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Table 1. Clinical characteristics of 199 type 1 diabetic patients with diabetic nephropathy and 188 type 1 diabetic patients
with persistent normoalbuminuria
Nephropathy Normoalbuminuria P-value
Gender men/women 122/77 115/73 NS
Age years 40.969.6 42.8610.2 NS
Duration of diabetes years 27.767.9 26.868.6 NS
HbA1c % 9.661.5 8.561.1 ,0.001
Urinary albumin excretion rate mg/24 h 796 8 —
(range) (16–14.545) (1–30) —
SCr lmol/L 103 76 ,0.001
(range) (54–684) (40–116) —
GFR mL/min/1.73 m2 75 — —
(range)* (10–143) — —
Systolic BP mm Hg 151623 132618 ,0.001
Diastolic BP mm Hg 86613 76610 ,0.001
Antihypertensive treatment % 76 12 ,0.001
Retinopathy† — — ,0.001
Nil 0 64 (34) —
Simplex 61 (31) 105 (56) —
Proliferative 138 (69) 19 (10) —
Abbreviations are: BP, blood pressure; HbA1c, hemoglobin A1c; GFR, glomerular filtration rate; SCr, serum creatinine. Data are expressed as means 6 SD; *,
medians (range); or †, N (%). Some patients with previously persistent albuminuria receiving antihypertensive medication had urinary albumin excretion rate ,300
mg/24 h, at the time of the investigation.
METHODS tion. Venous blood was drawn with minimal stasis from
an antecubital vein in ethylenediaminetetraacetic acidPatients
(EDTA) tubes. Centrifugation was performed at 1500 g
All Caucasian type 1 diabetic patients with diabetic for 10 minutes within an hour, and plasma stored at
nephropathy and more than 18 years of age, who had
2808C. Plasma VEGF levels were determined by a quan-
their glomerular filtration rate measured at Steno Diabe- titative sandwich enzyme immunoassay technique (Quan-
tes Center during 1993, were identified (N 5 242). No tikinee, R & D Systems Inc., Minneapolis, MN, USA).
additional exclusion criteria were applied. Blood samples The immunoassay used was designed to measure VEGF165,were obtained from 199 patients (122 men, 77 women) but as results from naturally occurring VEGF and recom-
with diabetic nephropathy, diagnosed clinically if follow- binant human VEGF121 showed linear curves parallel toing criteria were fulfilled: Persistent albuminuria .300 the standard curve of the Quantikine kit, the kit can be
mg/24 h in at least 2 out of 3 consecutive 24-hour urine used to determine relative mass values for natural human
collections, presence of diabetic retinopathy and no clini- VEGF isoforms. Samples were assayed in duplicate, and
cal or laboratory evidence of kidney or renal tract disease if results of duplicates differed more than 10% from
other than diabetic glomerulosclerosis [12, 13]. Of the their mean value, the assay was repeated. The minimum
199 nephropathic patients, 155 patients were followed detectable concentration of VEGF was 22.0 ng/L in our
for at least 3 years after the baseline examination with laboratory (approximately the concentration of lowest
yearly GFR measurements. standard). A subset of samples was analyzed with and
A group of 188 persistently normoalbuminuric (uri- without activation with hydrochloric acid as described
nary albumin excretion rate #30 mg/24 h) type 1 diabetic by Anthony et al [16]. Plasma sample (50 mL) and 0.6
patients (115 men, 73 women) matched for gender, age mol/L hydrochloric acid (25 mL) were mixed, added to
and duration of diabetes were recruited from our outpa- 100 mL of assay buffer and incubated in the microtiter
tient clinic and served as controls (Table 1). plate for 1 hour. The acid was neutralized with 25 mL of
All patients had been dependent on insulin from the 0.6 mol/L sodium hydroxide and incubated for a further 1
time of diagnosis and received at least two injections of hour. The assay procedure was then followed as de-
insulin daily. The local ethical committee approved the scribed by the manufacturer of the kit. By these analysis
experimental design, and all patients gave their informed results calculated by extrapolation of the standard curve
consent. were accepted. Urinary albumin concentration was de-
A more detailed description of the subjects studied is termined by ELISA [17] from 24 hour urine collections.
given in references [14] and [15]. Hemoglobin A1c (HbA1c) was determined from venous
blood samples by high performance liquid chromatogra-
Procedures phy (DIAMAT Analyzer, BIO-RAD, Richmond, CA,
All investigations were performed in the morning after USA). Normal range of HbA1c in our laboratory is
4.1–6.4%. Serum creatinine concentration was assessedan overnight fast, in an attempt to avoid diurnal varia-
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by a kinetic Jaffe’s method. Glomerular filtration rate thy group (69%) as compared with the normoalbumi-
nuric group (10%), P , 0.001. Data on VEGF are pre-was measured after a single intravenous injection of 3.7
MBq 51Cr-EDTA by determining the radioactivity in ve- sented in Table 2. In the patients with nephropathy, a
correlation between VEGF and diastolic blood pressurenous blood samples taken 180, 200, 220 and 240 minutes
after the injection [18] and the results were standardized (r 5 0.15, P 5 0.03) was found, whereas no correlation
between VEGF and blood pressure was present in thefor 1.73 m2 body surface area. Decline in GFR was calcu-
lated for all patients with yearly GFR measurements normoalbuminuric patients. Univariate analysis revealed
no correlations between level of VEGF and age, HbA1c,and a minimum of 3 years follow up. A linear regression
analysis was performed for each patient, and the slope urinary albumin excretion rate, or serum creatinine in
either group. Plasma levels of VEGF was significantlywas used to determine the rate of decline in GFR. Arterial
blood pressure was measured with a Hawksley random increased in patients with nephropathy as compared to
the normoalbuminuric group, P , 0.001. This differencezero sphygmomanometer (Hawksley & Sons Ltd, Lanc-
ing, Sussex, UK) and appropriate cuff size. The measure- was ascribed to elevated VEGF levels in men. We found
no difference in women with and without nephropathy,ments were performed twice, on the right arm, after at
least 10 minutes rest in the supine position and averaged. NS. No difference in plasma VEGF was observed between
patients receiving antihypertensive treatment at the timeDiastolic blood pressure was recorded at the disappear-
ance of Korotkoff sounds (phase V). Coronary heart of investigation and patients who were not taking blood
pressure lowering agents neither in the nephropathic nordisease was diagnosed based on electrocardiogram and
a World Health Organization questionnaire [15]. in the normoalbuminuric group (data not shown). Nor
were plasma VEGF significantly different in patients onRetinopathy was assessed by fundus photography
after pupillary dilatation and graded: nil, simplex or pro- ACE inhibition treatment, NS. When the nephropathic
and normoalbuminuric groups were dichotomized ac-liferative diabetic retinopathy.
cording to presence of coronary heart disease, no differ-
Statistical analysis ence in VEGF levels were revealed between patients
with or without coronary heart disease, NS.Plasma VEGF, urinary albumin excretion rate and
The group of patients with proteinuria and GFR aboveserum creatinine were non-normally distributed and val-
the median had a mean GFR of 102 6 19 mL/min/1.73ues are given as medians (range), and logarithmically
m2 and plasma VEGF of 45.0 [22.0–410] ng/L as com-transformed before analysis. All other values are given
pared with: mean GFR 46 6 18 mL/min/1.73 m2 andas means 6 SD. For normally distributed variables, com-
plasma VEGF of 46.0 [22.0–376] ng/L in proteinuric pa-parison between groups was performed by an unpaired
tients with GFR below the median, NS. In the 155 pa-Student’s t-test. For non-normally distributed, continu-
tients followed with yearly GFR measurements for atous variables, Mann–Whitney or Kruskal–Wallis test was
least three years (median 4.4 [range 3.0–5.4] years) follow-used for comparison between groups. A Chi-square test
up, we found univariate correlation between baselinewas used to compare frequencies. For baseline values,
values of log(albuminuria), arterial blood pressure anda multiple linear regression analysis was performed with
male gender, while HbA1c and log(plasma VEGF) didlog(VEGF) as dependent variable and backwards selec-
not act as predictors. When performing a multiple lineartion including all variables with P , 0.10 in univariate
regression analysis with rate of decline in GFR as depen-analysis. Linear regression analysis was used for calculat-
dent variable, including all variables with P , 0.10 ining rate of decline in GFR for the individual patient.
univariate analysis, only log (albuminuria) was includedMultiple regression analysis was performed with rate of
in the model, r 5 0.32. Plasma VEGF was below thedecline in GFR as dependent variable and backwards
detection limit (22.0 ng/L) in 60 patients with nephropa-selection including all variables with P , 0.10 in univari-
thy (30%) and 93 patients with normoalbuminuriaate analysis. A P-value , 0.05 (two-tailed) was consid-
(50%), P , 0.001.ered statistically significant. All calculations were per-
In the nephropathy group plasma levels of VEGF didformed with a commercially available statistics program,
not differ significantly between patients with simplexSPSS 8.0 (SPSS Inc., Chicago, IL, USA).
or proliferative retinopathy, P 5 0.10. No difference in
plasma VEGF was seen in normoalbuminuric patients
RESULTS with nil, simplex or proliferative retinopathy, NS. There
As shown in Table 1, patients with diabetic nephropa- was no significant difference in the proportion of patients
thy had elevated HbA1c, serum creatinine and blood pres- with plasma VEGF below the detection limit according
sure, as compared with the normoalbuminuric patients, to retinopathy in either group, NS. Plasma VEGF did not
P , 0.001. Twenty-four percent of the nephropathic pa- differ between patients with or without coronary heart
tients were spontaneously normotensive. The prevalence disease in either group, NS (data not shown). Acidification
and neutralization of samples before analysis increasedof proliferative retinopathy was higher in the nephropa-
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Table 2. Vascular endothelial growth factor (VEGF) in 199 type 1 diabetic patients with diabetic nephropathy and 188 type 1 diabetic
patients with persistent normoalbuminuria
Nephropathy Normoalbuminuria
N 5 199 N 5 188 P-value
VEGF ng/L
All patients 45.7 (22.0–410) 27.1 (22.0–355) 0.001
Men 51.8 (22.0–410) 22.0 (22.0–308) 0.001
Women 37.8 (22.0–325) 36.6 (22.0–355) NS
Plasma VEGF below detection limit
Men/women 33/27 61/32 P , 0.001
VEGF ng/L
No retinopathy — 23.9 (22.0–353.0)
Simplex retinopathy 55.4 (22.0–363.0) 27.3 (22.0–308.0)
Proliferative retinopathy 43.2 (22.0–410.0) 34.9 (22.0–113.0)
P 5 0.10 NS
Data are medians (range). Patients with values below the minimum detectable concentration of VEGF were assigned the lowest detectable value of 22.0 ng/L.
Table 3. Vascular endothelial growth factor (VEGF) in plasma after an acidification/neutralization step
Men Women
VEGF ng/L Normoalbuminuria Nephropathy Normoalbuminuria Nephropathy
Number of patients 7 9 10 9
Without acidification 27.5 (24.7–34.5) 24.1 (9.6–58.2) 37.8 (15.1–98.3) 40.7 (31.7–61.1)
With acidification 59.4 (55.2–69.1) 70.3 (39.2–97.3) 73.4 (46.6–138) 71.9 (56.8–143)
Increase in VEGF 30.6 (25.9–44.4) 34.3 (19.1–79.4) 26.6 (18.6–62.5) 24.5 (15.6–111)
Comparison between groups NS NS
Data are medians (range).
the VEGF values for all groups, Table 3. The samples nant women, while a radioimmunoassay could. Follow-
ing an acidification/neutralization step, VEGF could beused in this subanalysis were chosen so that the baseline
detected at the same level with both assays. We haveVEGF levels were comparable for normoalbuminuric
shown that acid treatment also increased the measurableand nephropathic men and women, respectively. The
concentration of VEGF in plasma from diabetic patients,increases in VEGF were similar in normoalbuminuric
supporting the existence of circulating VEGF bindingand nephropathic patients and in men and women.
proteins as suggested by Anthony et al [16]. The increase
seemed to be similar in men and women and in normoal-
DISCUSSION buminuric and nephropathic patients. The fact that
Our study revealed that plasma VEGF was elevated VEGF may exist as various alternatively splice variants,
in type 1 diabetic patients with diabetic nephropathy as in partially degraded forms and in complex with binding
compared with normoalbuminuric type 1 diabetic pa- proteins, complicates the evaluation of VEGF in plasma
tients. This difference in VEGF levels was ascribed to and serum. Due to the extremely low concentrations in
the difference in men. We detected no difference in which VEGF molecular species are found in biological
plasma VEGF when the patients with nephropathy were fluids, the current methodology is restricted to methods
divided by the median of GFR, suggesting that elevation measuring immunoreactivity. The assay we used applied
of plasma VEGF is an early phenomenon in the course of a monoclonal capture antibody directed against a do-
diabetic kidney disease. We found a positive correlation main common for all VEGF variants and polyclonal de-
between baseline values of albuminuria, arterial blood tecting antibodies. The assay therefore did not discrimi-
pressure, male gender and rate of decline in GFR in the nate between the different molecular forms of VEGF.
patients with diabetic nephropathy. HbA1c and plasma Whether the circulating VEGF immunoreactivity is bio-
VEGF did not act as risk factors for decline in kidney logically active is not known and will be very difficult to
function. Baseline albuminuria was the only predictor show due to the low concentrations. The highest concen-
of progression in diabetic kidney disease when evaluated trations observed in our study was about 400 ng/L, which,
in a multiple linear regression analysis. if it were native VEGF165, might stimulate human umbili-
Anthony et al [16] have shown that the ELISA assay cal vein endothelial cell proliferation under defined con-
from R & D Systems Inc., which is the assay we have ditions in vitro [19]. If active, the high levels found may
therefore have physiological relevance.used, was unable to detect VEGF in serum from preg-
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We have confirmed and extended previous studies on the observed large inter-individual variability in plasma
levels of VEGF in our study, an association which coulddiabetic kidney disease and circulating levels of VEGF
[20, 21]. Aziz et al reported elevated levels of VEGF in not be evaluated in all patients because kidney biopsies
were not available.a mixed population of 76 type 1 and type 2 diabetic
patients with and without microvascular complications as A previous study in humans by Aiello et al [10] have
reported elevated levels of VEGF in vitreous fluid incompared to 28 age-matched controls [20]. Furthermore,
they found a weak correlation (r 5 0.27, P , 0.05) be- active proliferative retinopathy as compared with quies-
cent proliferative diabetic retinopathy and non-prolifera-tween the level of albuminuria and serum VEGF. In
accordance, Wasada et al [21], found a tendency towards tive retinopathy. The elevated levels of VEGF declined
after successful laser photocoagulation. The absence ofincreasing levels of VEGF with increasing levels of albu-
minuria in 110 type 2 diabetic patients, of whom 31 elevated levels of VEGF in our patients with prolifera-
tive diabetic retinopathy could be attributed to the factpatients were macroalbuminuric and 42 patients had mi-
croalbuminuria. Plasma VEGF was higher in the micro- that nearly all of our patients with proliferative diabetic
retinopathy had previously undergone laser treatment,and macroalbuminuric groups compared with the nor-
moalbuminuric patients (P 5 0.03). In a recent study, and consequently they were not in a state of active prolif-
erative diabetic retinopathy. Furthermore, elevated VEGFurinary VEGF levels were significantly correlated to the
degree of proteinuria (r 5 0.297) in patients with diabetes levels in the vitreous fluid in the eyes of patients with
proliferative diabetic retinopathy has been reported to(abstract; Cha et al, J Am Soc Nephrol 10:A3428, 1999).
In the present study, we did not measure urinary levels be produced locally by the ischemic retina, whereas circu-
lating VEGF was not elevated [28]. A role for VEGF inof VEGF.
The difference in VEGF levels between the nephro- the pathogenesis of diabetic retinopathy is possible, since
VEGF might act predominately as a paracrine hormone.pathic and the normoalbuminuric patients in our study
was ascribed to a difference in men. Since VEGF has The decline in GFR in diabetic nephropathy is highly
variable, ranging from 2 to 20 mL/min/year [29–31]. Thisbeen shown to be elevated and positively correlated to
serum progesterone in early pregnancy [22], one can variability can partly be explained by so called progres-
sion promoters, i.e., risk factors for loosing filtrationsuggest that the menstruation cycle could be a con-
founder, and thereby mask the possible difference in power. Evaluation of progression promoters can take
place at the start of the study or during the course of theVEGF levels in female patients. In addition, atheroscle-
rosis and neuropathy have been suggested to increase study. Baseline progression promoters were evaluated in
the Captopril Collaborative study including 409 type 1circulating VEGF [23, 24], and thereby be possible con-
founders. However, the presence of coronary heart dis- diabetic patients with diabetic nephropathy, median fol-
low-up time of three years. A number of clinical andease is unlikely to confound our results, since VEGF
was not associated with that condition in our study. laboratory risk factors that predict doubling of serum
creatinine was found, including elevated mean arterialBecause no difference in plasma VEGF was seen be-
tween nephropathic patients with preserved or reduced blood pressure, high blood glucose, increased serum cre-
atinine, enhanced proteinuria and presence of edemaGFR, the elevated VEGF cannot be explained by deteri-
oration in kidney function. Our data suggest that the [32]. In our study, baseline albuminuria, arterial blood
pressure, and male gender were found to predict the rateelevation of VEGF occurs early in the course of diabetic
kidney disease. Similarly, in a biopsy study of non-dia- of decline in GFR, whereas only albuminuria was an
independent predictor of progression in kidney disease.betic human glomerulonephritis it was shown that VEGF
is elevated early in the course of this disease, and that We could not identify plasma VEGF at baseline as a
progression promoter in diabetic nephropathy in type 1VEGF activity may promote protein leakage from glo-
merular capillaries [25]. In another biopsy study of mixed diabetic patients. Progression promoters during the course
of diabetic kidney disease were evaluated by Rossingglomerular diseases including diabetic nephropathy, glo-
meruli with well-preserved architecture had a strong [33], and may be listed as follows: arterial hypertension,
albuminuria, glycemic control, dyslipidemia, smoking,VEGF protein expression, whereas in sclerotic areas, the
VEGF-expressing cells were markedly decreased [26]. and angiotensin-converting enzyme insertion deletion
polymorphism.Damaged cells have the potential for releasing large
amounts of stored VEGF, which may contribute to the In summary, we found elevated levels of VEGF early
in the course of diabetic nephropathy in men with typeincreased glomerular permeability seen in active glomer-
ular diseases [26]. Both these studies found elevated local 1 diabetes mellitus. Baseline albuminuria, arterial blood
pressure and male gender was found to be predictors oflevels of VEGF early in the disease process. Further-
more, Gro¨ne et al [27] found an increased expression of progression in diabetic nephropathy, while VEGF and
HbA1c did not contribute. The importance of VEGFVEGF mRNA in viable podocytes from diabetic pa-
tients, whereas a reduced or absent expression was seen in the initiation of diabetic nephropathy remains to be
established.in sclerotic glomeruli. This might contribute to explain
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